Exencial Wealth Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.3M Buy
81,932
+1,076
+1% +$28.6K 0.07% 208
2025
Q4
$2.01M Buy
80,856
+1,110
+1% +$28K 0.06% 223
2025
Q3
$2.03M Buy
79,746
+9,198
+13% +$227K 0.07% 217
2025
Q2
$1.71M Sell
70,548
-6,168
-8% -$144K 0.06% 232
2025
Q1
$1.94M Buy
76,716
+1,254
+2% +$32.8K 0.07% 216
2024
Q4
$2M Sell
75,462
-1,614
-2% -$43.8K 0.07% 207
2024
Q3
$2.23M Sell
77,076
-5,233
-6% -$153K 0.08% 204
2024
Q2
$2.3M Buy
82,309
+1,761
+2% +$48.5K 0.09% 197
2024
Q1
$2.24M Sell
80,548
-15,408
-16% -$428K 0.08% 200
2023
Q4
$2.76M Sell
95,956
-8,694
-8% -$263K 0.11% 166
2023
Q3
$3.47M Sell
104,650
-8,898
-8% -$315K 0.17% 138
2023
Q2
$4.16M Buy
113,548
+823
+0.7% +$32K 0.19% 126
2023
Q1
$4.6M Sell
112,725
-5,180
-4% -$224K 0.24% 112
2022
Q4
$6.04M Buy
117,905
+10,158
+9% +$487K 0.32% 92
2022
Q3
$4.71M Sell
107,747
-12,267
-10% -$596K 0.29% 104
2022
Q2
$6.29M Buy
120,014
+304
+0.3% +$15.5K 0.36% 90
2022
Q1
$6.2M Buy
119,710
+4,255
+4% +$221K 0.31% 109
2021
Q4
$6.82M Sell
115,455
-34,548
-23% -$1.71M 0.33% 107
2021
Q3
$6.45M Buy
150,003
+32,957
+28% +$1.46M 0.28% 94
2021
Q2
$4.58M Buy
117,046
+9,383
+9% +$365K 0.25% 118
2021
Q1
$3.9M Sell
107,663
-8,858
-8% -$315K 0.23% 134
2020
Q4
$4.29M Sell
116,521
-329,404
-74% -$12.1M 0.29% 108
2020
Q3
$15.5M Buy
445,925
+200,244
+82% +$7.02M 0.82% 34
2020
Q2
$7.62M Buy
245,681
+192,839
+365% +$6.55M 0.66% 39
2020
Q1
$1.64M Buy
52,842
+4,986
+10% +$170K 0.29% 86
2019
Q4
$1.78M Sell
47,856
-1,258
-3% -$44.8K 0.31% 94
2019
Q3
$1.67M Buy
49,114
+4,853
+11% +$176K 0.36% 83
2019
Q2
$1.82M Hold
44,261
0.42% 71
2019
Q1
$1.78M Buy
44,261
+10,258
+30% +$411K 0.42% 73
2018
Q4
$1.41M Sell
34,003
-4,218
-11% -$175K 0.38% 75
2018
Q3
$1.6M Sell
38,221
-1,829
-5% -$70.4K 0.37% 71
2018
Q2
$1.38M Sell
40,050
-399
-1% -$13.6K 0.38% 71
2018
Q1
$1.36M Sell
40,449
-2,446
-6% -$84.1K 0.41% 68
2017
Q4
$1.47M Buy
42,895
+1,171
+3% +$39.9K 0.44% 65
2017
Q3
$1.41M Sell
41,724
-201
-0.5% -$6.46K 0.47% 66
2017
Q2
$1.34M Sell
41,925
-1,358
-3% -$42.8K 0.55% 53
2017
Q1
$1.38M Sell
43,283
-1,556
-3% -$49.1K 0.6% 52
2016
Q4
$1.38M Buy
44,839
+4,974
+12% +$152K 0.59% 54
2016
Q3
$1.2M Buy
39,865
+704
+2% +$23.5K 0.53% 56
2016
Q2
$1.31M Buy
39,161
+2,957
+8% +$94.4K 0.59% 56
2016
Q1
$1.02M Buy
36,204
+420
+1% +$12K 0.48% 64
2015
Q4
$1.05M Buy
35,784
+2,010
+6% +$63.2K 0.52% 58
2015
Q3
$1.01M Sell
33,774
-1,196
-3% -$38.3K 0.49% 64
2015
Q2
$1.15M Sell
34,970
-1,804
-5% -$58.8K 0.73% 44
2015
Q1
$1.23M Sell
36,774
-305
-0.8% -$9.7K 0.52% 62
2014
Q4
$1.15M Buy
37,079
+1,072
+3% +$30.7K 0.51% 60
2014
Q3
$1.01M Buy
36,007
+391
+1% +$11K 0.45% 66
2014
Q2
$1.01M Sell
35,616
-1,584
-4% -$45.2K 0.43% 68
2014
Q1
$1.06M Buy
37,200
+356
+1% +$10.6K 0.44% 72
2013
Q4
$1.09M Buy
36,844
+14
+0% +$407 0.5% 65
2013
Q3
$1.09M Sell
36,830
-2,076
-5% -$56.5K 0.51% 63
2013
Q2
$1.08M Buy
+38,906
New +$1.07M 0.54% 61

Other funds holding PFE

Exencial Wealth Advisors's PFE Position: Q1 2026 in Review

Exencial Wealth Advisors increased its Pfizer (PFE) stake by 1.3% in Q1 2026, buying an estimated $28.6K and bringing the position to 81,932 shares worth $2.3M. The position accounts for 0.07% of the portfolio, ranked #208.

Exencial Wealth Advisors first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $15.5M in Q3 2020. 2,953 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Exencial Wealth Advisors held 81,932 shares of Pfizer worth $2.3M as of Q1 2026.
  • Exencial Wealth Advisors bought 1,076 Pfizer shares in Q1 2026, an estimated $28.6K.
  • Pfizer made up 0.07% of Exencial Wealth Advisors's portfolio in Q1 2026, its #208 holding.
  • Exencial Wealth Advisors first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Exencial Wealth Advisors's Pfizer position peaked at $15.5M in Q3 2020.
  • 2,953 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Exencial Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.